New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:00 EDTCGENCompugen appoints Avihai Shen as interim CFO
Compugen announced the appointment of Avihai Shen as Interim CFO, replacing Dikla Czaczkes Axselbrad. Anat Cohen-Dayag, Compugen’s President and CEO, stated, “The company and Dikla agreed that Dikla would step down from her position as the company’s CFO. We thank her for her contributions and wish her every success in her future endeavors.”
News For CGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
07:04 EDTCGENCompugen says CGEN-15049 'promising candidate' for cancer immunotherapy
Compugen disclosed results from recent studies further confirming CGEN-15049 as a "promising" target candidate for cancer immunotherapy. These recent studies evaluated the function of this Compugen-discovered immune checkpoint candidate on immune cells derived from the tumor environment of melanoma patients. Based on these and earlier experimental results, CGEN-15049 is further advancing in the company’s Pipeline Program, with ongoing therapeutic antibody development activities against this novel target. In the recent experimental studies now being disclosed, CGEN-15049 continued to demonstrate the potential to inhibit the immune system’s ability to attack cancer cells. More specifically, these studies have shown that overexpression of CGEN-15049 in human melanoma cells inhibits the activity of tumor antigen-specific cytotoxic T cells derived from melanoma patients’ tumors. The results suggest that CGEN-15049 can inhibit the activity of the immune system in the tumor microenvironment through its impact on TILs, which would otherwise fight the tumor.
September 29, 2014
07:05 EDTCGENCompugen presents results for CGEN-15001
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use